Octagon reports 6.5% stake in Gossamer Bio
Gossamer Bio, Inc. received an updated large-holder disclosure from Octagon Capital.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Gossamer Bio, Inc. received an updated large-holder disclosure from Octagon Capital. Octagon Capital Advisors LP, Octagon Investments Master Fund LP, and Ting Jia jointly report beneficial ownership of 15,141,425 Gossamer Bio common shares, representing 6.5% of the outstanding stock.
This stake includes 13,915,371 common shares held by the Master Fund and warrants to purchase up to 1,226,054 additional shares at an exercise price of $2.04 per share, expiring on July 24, 2028. The ownership percentage is based on 231,456,247 shares outstanding as of October 31, 2025, plus the warrant shares.
The reporting persons state that the securities were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of Gossamer Bio.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake in Gossamer Bio (GOSS) does Octagon report on this Schedule 13G/A?
How is the 6.5% ownership in Gossamer Bio (GOSS) calculated in this Schedule 13G/A?
Who are the reporting persons in the Gossamer Bio (GOSS) Schedule 13G/A filing?
Does Octagon intend to influence control of Gossamer Bio (GOSS) with this ownership?
AI-generated analysis. How Rhea-AI works. Not financial advice.